BG103740A - Phytostyrene composition for the prevention of the alzheimer's disease - Google Patents

Phytostyrene composition for the prevention of the alzheimer's disease

Info

Publication number
BG103740A
BG103740A BG103740A BG10374099A BG103740A BG 103740 A BG103740 A BG 103740A BG 103740 A BG103740 A BG 103740A BG 10374099 A BG10374099 A BG 10374099A BG 103740 A BG103740 A BG 103740A
Authority
BG
Bulgaria
Prior art keywords
composition
phytostyrene
alzheimer
disease
prevention
Prior art date
Application number
BG103740A
Other languages
Bulgarian (bg)
English (en)
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of BG103740A publication Critical patent/BG103740A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG103740A 1997-12-18 1999-09-17 Phytostyrene composition for the prevention of the alzheimer's disease BG103740A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (1)

Publication Number Publication Date
BG103740A true BG103740A (en) 2000-05-31

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103740A BG103740A (en) 1997-12-18 1999-09-17 Phytostyrene composition for the prevention of the alzheimer's disease

Country Status (18)

Country Link
US (1) US5985936A (no)
EP (1) EP0967982A2 (no)
CN (1) CN1252724A (no)
AU (1) AU1656099A (no)
BG (1) BG103740A (no)
BR (1) BR9807577A (no)
CA (1) CA2281710A1 (no)
EE (1) EE9900354A (no)
GE (1) GEP20022783B (no)
HU (1) HUP0100737A3 (no)
LT (1) LT4801B (no)
LV (1) LV12438B (no)
MD (1) MD1920F2 (no)
NO (1) NO993979L (no)
PL (1) PL335421A1 (no)
RU (1) RU2173151C2 (no)
SK (1) SK112999A3 (no)
WO (1) WO1999032097A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
CA2389973A1 (en) * 1999-11-04 2001-05-10 Andrx Corporation Method of treating amyloid beta precursor disorders
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
RU2303373C2 (ru) 2000-04-14 2007-07-27 Марс, Инкорпорейтед Композиции и способы улучшения состояния сосудистой системы
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
JP2007526764A (ja) * 2004-01-22 2007-09-20 ジェネッサンス ファーマシューティカルズ，インコーポレイティド アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
JP4849642B2 (ja) * 2004-11-24 2012-01-11 ネオプロ ラブス， エルエルシー 状態を処置するための方法および組成物
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
RU2297860C1 (ru) * 2006-02-07 2007-04-27 Иван Васильевич Максимович Способ эндоваскулярного лечения болезни альцгеймера
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2012149111A1 (en) * 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
WO2021130002A1 (en) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Food supplement for alzheimer
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
RU2165431C2 (ru) * 1994-09-29 2001-04-20 Дзе Юниверсити оф Бритиш Колумбия Способ выделения композиции фитостеролов, композиции, терапевтический продукт
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
AU7580098A (en) * 1997-05-15 1998-12-08 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
HUP0100737A2 (hu) 2001-09-28
HUP0100737A3 (en) 2002-07-29
WO1999032097A2 (en) 1999-07-01
MD990262A (en) 2000-06-30
LT4801B (lt) 2001-06-25
EP0967982A2 (en) 2000-01-05
SK112999A3 (en) 2001-11-06
CA2281710A1 (en) 1999-07-01
NO993979D0 (no) 1999-08-18
MD1920F2 (ro) 2002-05-31
PL335421A1 (en) 2000-04-25
LT99114A (lt) 2001-01-25
BR9807577A (pt) 2001-08-07
EE9900354A (et) 2000-02-15
CN1252724A (zh) 2000-05-10
AU1656099A (en) 1999-07-12
LV12438B (en) 2000-09-20
LV12438A (en) 2000-03-20
NO993979L (no) 1999-10-13
US5985936A (en) 1999-11-16
GEP20022783B (en) 2002-09-25
WO1999032097A3 (en) 1999-09-02
RU2173151C2 (ru) 2001-09-10

Similar Documents

Publication Publication Date Title
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
MY132529A (en) Paroxetine hydrochloride anhydrate
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
BG103646A (en) Arylsulphonamides, their analogues and application for the treatment of neurodegenerative diseases
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BG102259A (en) Compostions with controlled paroxetine release
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
IL116746A0 (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
BG105197A (en) Polymorph form of a medicament
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BG105275A (en) Tan-1057 derivatives
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
BG102667A (en) Diosgenine-containing composition
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin